ADMA Biologics (NASDAQ:ADMA) Posts Earnings Results, Hits Expectations

ADMA Biologics (NASDAQ:ADMA) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.20 earnings per share for the quarter, meeting the consensus estimate of $0.20, FiscalAI reports. The business had revenue of $139.16 million during the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a net margin of 42.87% and a return on equity of 36.52%. The firm’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.46 EPS.

Here are the key takeaways from ADMA Biologics’ conference call:

• Total revenue of $510.2M in 2025 with adjusted EBITDA of $231M (+40% YoY) and adjusted net income of $160.8M (+35% YoY), and corporate gross margins expanding to 57.4% for the year (63.8% in Q4), signaling stronger profitability and operating leverage.
• Asceniv drove growth, generating $363M in 2025 (+51% YoY), representing roughly a 70/30 split versus Bivigam and positioned as the main growth engine with substantial upside as it remains early in its penetration curve.
• The company operationalized yield‑enhanced production in 2025 and expects 2026 to be the first full year of higher-yield output, which management says will materially improve gross margins and earnings power.
• ADMA restructured its plasma network by agreeing to monetize three centers while retaining seven and securing third‑party supply agreements that provide access to over 280 plasma collection centers, improving long‑term high‑titer supply visibility into the late 2030s.
• Working capital and accounts receivable rose with rapid Asceniv growth (company expects AR/DSO to improve through 2026 as McKesson distribution ramps), cash was $88M at year‑end excluding divestiture proceeds, and management issued robust multi‑year guidance (2026 revenue >$635M, adjusted EBITDA >$360M) while noting the divestiture remains on track to close this quarter.

ADMA Biologics Stock Down 3.2%

Shares of NASDAQ ADMA traded down $0.50 during mid-day trading on Thursday, hitting $15.18. 7,477,169 shares of the stock traded hands, compared to its average volume of 2,473,152. The company has a market cap of $3.61 billion, a price-to-earnings ratio of 17.65 and a beta of 0.49. The stock has a fifty day moving average price of $17.41 and a 200-day moving average price of $16.83. ADMA Biologics has a 52 week low of $13.50 and a 52 week high of $25.67. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.65 and a current ratio of 7.13.

Institutional Trading of ADMA Biologics

Hedge funds have recently modified their holdings of the business. Corient Private Wealth LLC increased its stake in shares of ADMA Biologics by 58.0% in the 4th quarter. Corient Private Wealth LLC now owns 91,367 shares of the biotechnology company’s stock worth $1,667,000 after acquiring an additional 33,541 shares in the last quarter. Vident Advisory LLC grew its holdings in ADMA Biologics by 24.2% in the fourth quarter. Vident Advisory LLC now owns 270,492 shares of the biotechnology company’s stock worth $4,934,000 after purchasing an additional 52,687 shares during the period. First Citizens Bank & Trust Co. increased its stake in shares of ADMA Biologics by 24.4% during the fourth quarter. First Citizens Bank & Trust Co. now owns 48,763 shares of the biotechnology company’s stock valued at $889,000 after purchasing an additional 9,576 shares in the last quarter. Cim LLC increased its stake in shares of ADMA Biologics by 3.2% during the fourth quarter. Cim LLC now owns 94,379 shares of the biotechnology company’s stock valued at $1,721,000 after purchasing an additional 2,893 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $395,000. Institutional investors own 75.68% of the company’s stock.

More ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: Management forecasted robust 2026 revenue (around $635M) and said Asceniv sales will continue to drive margin expansion and new supply deals that extend the growth runway. This outlook supports higher future revenue expectations and is a primary bullish catalyst. Article Title
• Neutral Sentiment: Company reported record Q4 and full-year 2025 results with 18% Q4 revenue growth and an EPS that matched consensus ($0.20), but revenue was slightly below Street expectations — a mixed beat/meet that tempers immediate upside. Article Title
• Neutral Sentiment: Full earnings conference call transcript and previews are available for investors who want detail on drivers and guidance assumptions; these resources help assess whether the 2026 projection is achievable. Article Title
• Negative Sentiment: Despite revenue growth, profitability and cash metrics showed strain: net income and EPS fell sharply year-over-year, operating cash flow plunged (~73.5%), capex rose materially and cash balances declined — signs that near-term cash generation is weaker even as sales scale. Additionally, significant insider selling was reported, which can weigh on sentiment. Article Title
• Neutral Sentiment: Short-interest reports in recent days appear anomalous (reporting zeros/NaN), so there’s no clear short-squeeze dynamic evident from the available data; treat the short-interest numbers as unreliable until clarified.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $28.50.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.